Cargando…
Efficacy and safety of radiotherapy plus anti-PD1 versus transcatheter arterial chemoembolization plus sorafenib for advanced hepatocellular carcinoma: a real-world study
BACKGROUND: The combination of transcatheter arterial chemoembolization (TACE) plus sorafenib prolonged progression-free survival (PFS) and overall survival (OS) than sorafenib or TACE monotherapy for patients with hepatocellular carcinoma (HCC). This study assessed the efficacy and safety of radiot...
Autores principales: | Li, Jian-Xu, Deng, Wen-Xiang, Huang, Shi-Ting, Lin, Xiao-Feng, Long, Mei-Ying, Zhang, Jie, Su, Ting-Shi, Li, Li-Qing, Pang, Ya-Dan, Liang, Chun-Feng, Zhou, Hong-Mei, Lu, Hai-Yan, Liang, Shi-Xiong, Xiang, Bang-De |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9188229/ https://www.ncbi.nlm.nih.gov/pubmed/35690773 http://dx.doi.org/10.1186/s13014-022-02075-6 |
Ejemplares similares
-
Radiotherapy plus anti-PD1 versus radiotherapy for hepatic toxicity in patients with hepatocellular carcinoma
por: Zhang, Rui-Jun, et al.
Publicado: (2023) -
Transcatheter arterial chemoembolization plus sorafenib versus transcatheter arterial chemoembolization alone to treat advanced hepatocellular carcinoma: a meta-analysis
por: Cai, Rong, et al.
Publicado: (2017) -
Safety and Efficacy of Transcatheter Arterial Chemoembolization Plus Radiotherapy Combined With Sorafenib in Hepatocellular Carcinoma Showing Macrovascular Invasion
por: Zhao, Yuting, et al.
Publicado: (2019) -
The Efficacy of Transarterial Chemoembolization plus Apatinib or Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma
por: Chen, Lei, et al.
Publicado: (2021) -
Sorafenib plus transarterial chemoembolization for unresectable hepatocellular carcinoma
por: Tsilimigras, Diamantis I., et al.
Publicado: (2020)